Fairvalue-Calculator Fairvalue-Calculator
EN DE

CellaVision AB (CEVI) Fair Value & Analysis

Healthcare · SE · Market cap 3.0B SEK

Pricekr 138.40
Fair Valuekr 141.19
Upside+2.0%
Quality95/100
Evidence: High Range kr 103.89 – kr 176.49

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

CellaVision AB (CEVI) currently trades at kr 138.40, while our model-based Fair Value estimate is kr 141.19 — implying the stock looks roughly 2.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears;…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is CellaVision AB (CEVI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 141.19 versus a price of kr 138.40 — about +2% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CEVI?
Our 21-model fair value for CellaVision AB is kr 141.19 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 138.40.
What is the quality score of CEVI?
CellaVision AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.